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ABSTRACT
The adrenergic hormones norepinephrine (NE) and epinephrine (EPI) are
essential for cardiovascular development as embryos lacking NE/EPI begin to die
abruptly between embryonic days 10.5 and 11.5 due to apparent cardiac failure. The
objective of this research aims to elucidate the mechanism of the embryonic fatality
observed in the NE/EPI deficient mouse model. Here we utilized the dopamine βhydroxylase knockout (Dbh-/-) mouse model, which lacks the gene and subsequent
enzyme necessary for the conversion of dopamine to norepinephrine. Embryonic
mouse hearts were extracted from Dbh+/+ (control) and Dbh-/- (experimental model)
mice for mRNA transcript expression profiling. These studies were performed using the
Affymetrix Mouse Genome 430A 2.0 Arrays and quantitative real-time RT-PCR. Gene
expression data suggest a novel connection between the ability of the heart to
synthesize adrenergic hormones and the gene expression of enzymes involved in the
synthesis of retinoic acid. Specifically, we found a statistically significant change in
transcriptional expression of the retinol binding protein-1 (Rbp-1), retinol dehydrogenase
12 (Rdh-12) and beta carotene monooxygenase-1 (Bcmo-1) genes in the E10.5 Dbh-/mouse heart. The gene expression of Rbp-1 and Rdh-12 were increased 1.4 fold and
2.1 fold on the microarray, respectively. The proteins translated from these genes play
central roles in the transport and enzymatic conversion of precursor molecules in the
pathway of retinoic acid biosynthesis. Additionally, we found that the expression of
Bcmo-1, an enzyme responsible for the breakdown of beta carotene to the retinoic acid
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precursor retinal, was down regulated 2.7 fold in the Dbh-/- heart based on microarray
assessment. Bcmo-1 is a well known retinoic acid responsive gene, suggesting that the
loss of adrenergic hormones in the Dbh-/- mouse heart may result in a deregulation of
retinoic acid synthesis and further an alteration in the concentration of retinoic acid
present in the embryonic tissue of adrenergic hormone deficient embryos.
In addition, we utilized a genetic mouse model that expresses β-galactosidase
(β-Gal) in cells capable of synthesizing epinephrine in order to identify the spatial and
temporal distribution of adrenergic-derived cells in the developing heart. The model
was designed so that cells capable of expressing the gene phenylethanolamine Nmethyltransferase (Pnmt), which is responsible for the synthesis of epinephrine, also
produce the enzyme β-Gal as a reporter. The resulting presence of the β-Gal enzyme
can be visualized using a β-Gal substrate called XGAL, which is converted into a blue
precipitate when cleaved by the β-Gal enzyme. Evaluation of the location of these cells
in the embryonic heart showed a preferential distribution at the atrioventricular sulcus at
E10.5, and later at E18.5 a more widely distributed ventricular pattern was observed. In
addition, the right atrium showed a cluster of XGAL positive cells (blue cells) near the
region of the sinoatrial node, while the distribution of XGAL positive cells in the left
atrium was quite diffuse. Interestingly, when the adult heart was examined, it was
discovered that cells capable of synthesizing epinephrine (adrenergic-derived) are
found predominately on the left side of the heart. This left-sided distribution appears to
be non-random and non-uniform, since specific regions are consistently XGAL positive,
but not every cell in each region. Whole mount and 3-dimensional reconstruction of the
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β-Gal staining showed that these cells traverse the depth of the heart at the midventricular and apical regions. This finding is quite interesting and may provide new
knowledge about the functional and structural characteristics of the adult heart. One
observation is that these cells may contribute to the cardiomyopathy known as TakoTsubo or “Broken Heart” syndrome. The syndrome is characterized by left ventricular
dysfunction during bouts of stress. Also, of particular intrigue is the anatomical
correlation of the adrenergic derived cells and the helical ventricular myocardial band
(HVMB). Careful examination of the spatial and directional pattern of these cells within
the myocardium suggests they contribute primarily to a specific section of the HVMB.
The significance of this finding is yet to be uncovered.
Taken collectively, this study has shown a novel connection between two crucial
developmental signaling pathways. Adrenergic hormone and retinoic acid signaling can
now be viewed as cooperative partners in the development of the embryonic heart. In
addition, this study has also shown that adrenergic derived cells in the adult heart have
a distinctive left-sided distribution, which is non-random, non-uniform, and shows
interesting features suggesting an anatomical connection to the HVMB and a clinical
association to Tako-Tsubo syndrome. These findings will appreciably contribute to the
knowledge base of the scientific community.
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CHAPTER 1 ADRENERGIC HORMONES IN THE DEVELOPING HEART

General Introduction

Heart disease is the leading cause of death in the United States. It has been
declared an epidemic by several institutions including the Center for Disease Control,
National Institute of Health and the American Heart Association. Each institute has
enhanced there research efforts to uncover the cultural, socioeconomic, and molecular
basis of heart disease. In the U.S. alone, approximately 40 % of the total annual deaths
are attributed to some type of heart disease [1]. This translates to more than 600,000
people who have died from heart disease in the past 12 months. Sadly, infants account
for an unmerited percentage of those deaths. Congenital heart defects are estimated to
arise in 28,000 births and will result in an additional 25,000 embryonic fatalities this year
in the Unites States [2]. For these reasons, researchers are working diligently to
understand the complexity of heart disease, and to develop strategies to battle the
mortality rate this terrible condition encompasses.
Studies of the molecular mechanisms underlying heart failure have led to many
new and interesting discoveries. In the past decade, protein expression studies have
revealed that heart disease has a proteomic profile, much like that observed in many
cancers. Particular proteins of interest include; C-reactive protein (CRP), monocyte
chemo-attractant protein-1 (MCP-1), and insulin-like growth factor binding protein [3] [4]
[5]. These among others have been directly associated with known degenerative
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mechanisms of heart failure and are prime targets for future clinical therapeutics. The
goal of the current study is to append such novel molecular findings and further our
understanding of the principal mechanisms of cardiac development and disease.
Adrenergic hormones have long been associated with physiological reactions,
including the well known reactions associated with our flight or fight response. There
are two classical adrenergic hormones; norepinephrine (NE) and epinephrine (EPI).
The adrenergic hormones NE and EPI act as neurotransmitters in the nervous system
and as hormones in the endocrine system. Together, NE and EPI facilitate many
physiologic functions of the human body.
The principal locations of adrenergic hormone synthesis are the medulla of the
adrenal glands, and the postganglionic terminals of the nervous system [6]. Hormonal
activity of NE and EPI is mediated through secretion directly into the blood stream
where these hormones bind the alpha adrenergic receptors (α1, α2), and/or the beta
adrenergic receptors (β1, β2, and β3). Receptor binding results in downstream
signaling events such as; the activation of protein kinases A and C, calcium storage
release in muscle cells, and the activation of phosphorylases which initiate the
breakdown glycogen [7] [8]. In this manner, adrenergic hormones play a major role in
the body‟s homeostasis control. Some of the physiological changes include but are not
limited to; increased heart rate, vasodilatation, vasoconstriction, sweating, increased
respiration, iris dilation and decreased movement within the GI tract [9].
The enzymes responsible for the synthesis of adrenergic hormones are tyrosine
hydroxylase (TH), dopa decarboxylase (DDC), dopamine β-hydroxylase (DBH), and
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phenylethanolamine N-methyltransferase (PNMT) in their respective order of
epinephrine generation from the precursor molecule tyrosine (Figure 1). Three of these
enzymes have been genetically disrupted in the mouse model, which has giving rise to
three different phenotypic profiles. The Th knockout (Th-/-) mouse model is deficient of
dopamine (DA) and the downstream end products NE and EPI. The Th-/- phenotype is
embryonic lethal with 75-100 % fatality in utero due to apparent cardiovascular failure
beginning at embryonic days 11.5 [10].

Figure 1. Adrenergic hormone synthesis. Synthesis pathway of the adrenergic
hormones norepinephrine and epinephrine from the amino acid tyrosine.
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Interestingly, the Dbh knockout (Dbh-/-) mice, which produce the monoamine DA
but not NE or EPI, show a slightly more severe phenotype than the Th-/- mouse model,
as they begin to die one day earlier and less than 50 % of the embryos survive to
embryonic day 15.5, with a limited occurrence of survival to birth [11]. Conversely, the
Pnmt-/- mice do not appear to have a salient phenotype, as they survive to birth and
appear normal [12]. These findings indicate a critical necessity for NE availability during
embryonic development.
Detailed studies of the Dbh-/- mouse model have shown that NE is critical for
embryonic survival beyond embryonic day 10.5, since half of the Dbh-/- mice die
between E10.5 and E11.5. This would represent a period equivalent to 4 - 5 weeks in
human fetal development, and is the time immediately following the initial onset of the
embryonic heart beat [13]. The reason for the observed embryonic fatality in the Dbh-/mouse model has been attributed to cardiac failure, although, of an unknown etiology
due to the lack of detectable structural abnormalities in the heart. Detailed analyses
have shown that the embryonic heart spontaneous begins to fail near mid-gestation,
exhibiting arrhythmogenesis plus cardiac and hepatic pooling of the blood [11]. It has
been suggested that the NE/EPI deficient mouse heart may fail due to severe hypoxia
and an inability to recover from hypoxic events in utero [14] [15]. This is a possible
mechanism of embryonic fatality because it is well established that adrenergic
hormones are released under hypoxic conditions to stimulate downstream effectors
responsible for survival during hypoxic stress [16].
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This study examined the underlying physiologic and genetic mechanisms
involved in the embryonic cardiac failure resulting from the genetic deletion of the Dbh
gene. In addition, fate-mapping strategies were used to investigate the localization of
cells capable of synthesizing adrenergic hormones in the developing mouse heart.
Adrenergic hormones and retinoic acid synthesis
Recently, genetic profiling of the Dbh-/- mouse heart has implicated the retinoic
acid signaling pathway as a participant in the embryonic lethal phenotype. Retinoic acid
is essential for normal embryonic development and plays a critical role in cellular
differentiation and gene transcription during early development. It has been shown to
play a central role in eye development, vision, CNS development, immune system
maintenance and specifically cardiac development [17] [18] [19] [20]. Vitamin A (retinol)
is one of the two primary dietary precursors of retinoic acid. The synthesis of retinoic
acid from vitamin A or retinol is achieved by the retinol dehydrogenase (RDH) family of
enzymes, which convert retinol to retinal via oxyreductase activity [21]. The other
retinoic acid precursor is beta carotene (β-carotene), which is enzymatic cleaved via the
enzyme beta carotene-15, 15 mono-oxygenase-1 (BCMO-1) to yield two identical
molecules of retinal [22]. The resulting retinal molecules can then be oxidized to
retinoic acid by the aldehyde dehydrogenase 2 (ALDH1A2) enzyme, formerly
retinaldehyde dehydrogenase 2 (RALDH2) [23], which is the rate limiting step in the
synthesis of retinoic acid in the embryonic mouse heart [18]
(Figure 2).
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Figure 2. Biosynthesis of retinoic acid. Synthesis pathway of retinoic acid and its
negative feedback loop with beta carotene monooxygenase.

During embryonic development, the location and concentration of retinoic acid is
stringently modulated by its‟ synthesizing and degradation enzymes to facilitate normal
development [17][24]. Disrupting the embryonic homeostasis of retinoic acid
concentration results in several abnormalities. Studies have shown that administration
of retinoic acid to embryonic tissue during embryogenesis leads to many disorders
including; craniofacial malformations, disruption of central nervous system (CNS)
development, cardiac development alterations, teratogenesis, and embryonic lethality
[25, 26]. Equally, a retinoic acid deficiency results in many similar developmental
abnormalities. These include; a disruption in A-P patterning of the CNS, abnormal liver
development, early hematopoeisis, and cardiac progenitor cell defects [27,28].
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The role of retinoic acid during these early stages of development is primarily
regulation of gene expression. The function of retinoic acid is mediated through the
retinoic acid receptors (RAR α, β, γ) and the retinoid X receptors (RXR α, β, γ) [26] [29].
These nuclear receptors form homozygous and heterozygous dimers with one another
and other nuclear receptor which bind to DNA at retinoic acid response elements
(RARE) or other response elements to regulate specific gene activation or suppression
[30,31]. In this manner, retinoic acid can act as an inducer or suppressor of gene
expression in a concentration and temporal dependent way [31, 32]. This reiterates the
necessity for stringent regulation of retinoic acid synthesis during embryonic
development.
Anatomical distribution of adrenergic derived cells in the mouse heart
The anatomical structure of the heart plays an important role in its function. The
phrase „Form predicts Function‟ has become central dogma in the land of biomedical
research. The developing heart is subject to, and a prime example of this principle.
The heart is a simple collection of cardiomyocytes, connective tissue, and neurons.
Yet, the structure and complex assembly of these cells make the heart an efficient
pump. Research into the architecture of the heart has shown that the cellular
orientation of cardiomyocytes in conjunction with fibrous connective tissue form
functional structural units called “laminas” [33]. These laminas, through autonomous
action supplement the action of surrounding laminae to generate an orchestrated
directional contraction of the heart resulting in an efficient and directed propulsion of
blood though the heart [34]. Francisco Torrent-Guasp unraveled the macro structure of
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the adult heart in a detailed stepwise manner which disassembled the myocardium
based on the natural direction and assembly of these laminar units. When fully
dismantled, the heart resembles a band much like that in which it originally began its
development. Dr. Guasp called it the “helical ventricular myocardial band” (HVMB) [35].
The cardiomyocytes of the heart have long been thought to function primarily as
mechanical units. However, studies have shown that basal levels of serum
norepinephrine remain steady after complete adrenalectomy, suggesting an alternative
source of systemic hormones [36]. The heart makes an idea candidate for an extraadrenal source of adrenergic hormones as it serves as the core of the circulatory
system. In 1996, Huang et al. introduced the term intrinsic cardiac adrenergic (ICA)
cells, for the sub population of cells in the heart capable of producing adrenergic
hormones [37]. These cells were found initially to be present in the embryonic heart at
E15.5 and were primarily associated with regions of the pace-making and conduction
tissue. These “ICA cells” appeared as early as embryonic day 8.5 (E8.5) in mice, and
are suspected to remain in the developing heart through neonatal stages of
development [12]. If these ICA cells are capable of producing the adrenergic hormones
NE and EPI, it is then feasible that they may also have the capability to secrete them.
So, the heart could in fact, be the source of norepinephrine found in the serum of
adrenalectomized animals.
This study determined whether cells capable of producing adrenergic hormones
remained in the heart beyond the embryonic stages of development. And whether ICA
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cells are co-localized with common structures of the neuronal system, such as the SA
node, AV node, or the bundle branches of the adult heart (figure 3).

Figure 3. Classical conduction system of the adult heart. The neuronal system of the
heart is necessary for the propagation of electrical signals from the parasympathetic
and sympathetic nervous system.
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CHAPTER 2 ADRENERGIC HORMONES AND RETINOIC ACID: A
NOVEL PAIR IN HEART DEVELOPMENT

Introduction

Adrenergic hormones play an essential yet unexplained role in mammalian heart
development during embryogenesis [10, 11]. In adult mammals, the primary adrenergic
hormones are norepinephrine (NE) and epinephrine (EPI), which serve as both
neurotransmitters and hormones. In the periphery, they are mainly produced in
sympathetic neurons and adrenal chromaffin cells, respectively [38], though they have
also been found to lesser extent in a number of other cells and tissues[39, 40]. They
are secreted during periods of stress where they bind and activate various - and adrenergic receptor subtypes leading to a myriad of physiological changes associated
with stress responses. In the mid 1990‟s, it was discovered that NE and/or EPI are vital
for embryonic survival in utero since disruption of the genes encoding for the
catecholamine biosynthetic enzymes, tyrosine hydroxylase (Th) or dopamine βhydroxylase (Dbh), resulted in an embryonic lethality due to apparent heart failure [10,
11]. In the absence of NE and EPI, embryos survive and appear relatively “normal” until
approximately embryonic day 10.5 (E10.5), but then begin to die over the next several
days with ~90% of the Dbh-/- mice not surviving to birth [11].
Examination of Th-/- and Dbh-/- embryos indicated that many of them had blood
congestion in the liver and major vessels, suggesting poor circulation [10]. In addition,
thinning of the atrial chamber walls and some disorganization of ventricular myocytes
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were also observed in these mutant embryos. Consequently, the heart appeared to
harbor relatively subtle morphological defects in the absence of adrenergic hormones,
but impairment and loss of function appear to be the primary reasons for the observed
demise of these adrenergic-deficient embryos.
Subsequent studies have shown suggested that adrenergic-deficient embryos
have an impaired ability to respond to intermittent hypoxia in utero [14, 15]. Adrenergiccompetent controls typically respond to hypoxia with adrenergic-mediated increases in
heart rate, but Th-/- mice cannot do this since they lack the ability to produce adrenergic
hormones. Consequently, this lack of responsiveness has been hypothesized to lead to
heart failure and death in Th-/- embryos [15]. This hypothesis is supported by additional
data showing that a number of known hypoxia-induced genes were significantly upregulated in E12.5 Th-/- embryos compared to littermate controls in response to hypoxic
conditions [15]. It is not entirely clear, however, that the developing embryo/fetus is
subjected to significant hypoxia during the course of a normal pregnancy. Further, the
bulk of the hypoxia-related experiments were performed between E11.5 to birth, yet
approximately 50% of adrenergic-deficient embryos die between E10.5 and E11.5.
Thus, there are some open questions about how catecholamines influence cardiac
function particularly at early stages of embryonic heart development.
We previously showed that disruption of the EPI-specific biosynthetic enzyme,
phenylethanolamine n-methyltransferase (Pnmt), results in a loss of EPI but do not
display any obvious developmental phenotype. Thus, NE appears to be the primary
catecholamine needed for embryonic survival. In the present study, we utilized the
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Dbh-/- mouse model to evaluate physiological and genetic changes associated with the
loss of NE and EPI during a critical early period of embryonic heart development
extending from E9.5-E12.5. We employed a combination of non-invasive highresolution ultrasonic imaging and genome-wide microarray analyses to evaluate cardiac
changes that occurred due to the absence of endogenous adrenergic hormones. The
results of these experiments suggest that mechanisms unrelated to or preceding
hypoxia-driven effects likely play an important role in mediating adrenergic signals
during critical early phases of embryonic heart development.

Methods

Animals
All procedures and care of the mice were conducted in accordance with National
Institutes of Health guidelines using protocols established by the Institutional Guidelines
for the Care and Use of Animals in Research. The genetic mouse model was
developed as previously described [11].
Ultrasonography
High resolution ultrasound imaging (Visualsonics Vevo 660 with 40 and 55 MHz
transducers) was used to measure physiologic heart rates from Dbh-/- and Dbh+/+
embryos in vivo.
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Embryonic tissue collection
For microarray studies, Dbh+/- sire and dam were mated generating Dbh+/+,
Dbh+/-, and Dbh-/- offspring in Mendelian ratios. For RA measurements, Dbh+/- sire
were mated with L-dihydroxyphenylserine rescued Dbh-/- dams to yield Dbh+/- and
Dbh-/- offspring at a predicted 50:50 ratio as previously described [11]. Timed
pregnancies yielded E9.5, E10.5, and E11.5 embryos which were used for these
studies. The embryos were examined for viability and the heart was visualized
microscopically for beating activity. Embryos with beating hearts were utilized for the
experiments described here. Embryonic hearts were extracted and immediately frozen
in liquid nitrogen unless used for ex vivo drug treated cultures. Embryonic hearts used
for ex vivo cultures were excised and rinsed in PBS then placed in pre dosed cardiac
differentiation media for 24 h culture. Genotype determination was carried out using
genomic DNA extracted from a fraction of the embryonic tissue.
RNA Isolation
Hearts collected for mRNA expression analysis were flash frozen in liquid
nitrogen. Frozen embryonic hearts were homogenized via sonication followed by
Trizol® RNA extraction, Sigma Aldrich (St. Louis, MO). Total RNA quality and yield was
assessed using the NanoDrop™ 1000. Only total RNA samples showing an
OD260/OD280 ratio higher than 1.75 were used for microarray and real-time PCR.
Microarray data analysis
Isolated RNA from frozen embryonic hearts was sent to AffyMetrix® (Santa
Clara, CA) for total genome analysis on the Mouse Genome 430A 2.0 Array. The data
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output was processed by Gene Logic (Gaithersburg, MD) and sent to our laboratory for
further analysis. We designed a data filtration algorithm which would generate a list of
genes that showed high probability of transcript presence and a statistically significant
change of mean signal between Dbh-/- and Dbh+/+ samples.
Real-time PCR analysis
Total RNA samples showing an OD260/OD280 ratio higher than 1.75 were used
for cDNA synthesis. Genomic DNA was removed from the isolated RNA by digestion
with RNase-free DNase (Promega, Madison, WI). The cDNA was prepared using
Affinity Script™ QPCR cDNA synthesis kit (600559, Stratagene, Cedar Creek, TX). We
used 0.4 μg total RNA for each cDNA synthesis reaction. Real-time PCR reactions
were performed using IQ SYBR Green super mix (Bio-Rad Hercules, CA) and run in the
Bio-Rad ICycler. Oligonucleotide sequences and annealing temperatures are shown in
table 1.
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Table 1. Oligomer sequences utilized for RT-PCR reactions including; GenBank®
accession ID, predicted product size, and annealing temperatures.

Retinoic acid bioassay
F9-RARE-LacZ cells were maintained in L-15 Leibovitz media containing 20%
heat inactivated, charcoal stripped Fetal Bovine Serum (FBS) and 1% PenStrep (V/V).
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The cells were grown to confluency (80- 90%) on 100 mm gelatin-coated dishes then
plated at 60% confluency on 24 well dishes and allowed to settle overnight.
Immediately before the assay individual embryonic trunks were homogenized via 5 s
sonication twice in F9-RARE-LacZ cell culture assay media (passage media plus 1.6
g/L D-glucose) under dim lighting. The homogenate was centrifuged at 8000g for 5 m
to removed cell debris before adding to the F9-RARE-LacZ cells. Before adding the
homogenate, the normal passage media was removed from the F9-RARE-LacZ cells
and 0.9 ml of assay media was added followed by 100 µl of the embryonic trunk
homogenate. The co-culture was allowed to incubate overnight at 37°C and 5% CO2.
For the detection of beta galactosidase activity using the fluorescein di-β-Dgalactopyranoside (FDG) substrate; co-cultured F9-RARE-lacZ cells were lysed in 100µl
of Z-buffer (0.8 g Na2HPO4, 0.28 g NaH2PO4, 0.5 ml 1M KCL, 0.05 ml 1M MgSO4 and
0.135 ml β-mercaptoethanol, all dissolved in dH2O to a volume of 50 ml) via 5 s
sonication and added to a 96 well plate with the addition of 2 µl of 1 mM FDG. The light
production was measured using the EnVision® Multilabel plate reader (PerkinElmer,
USA).
Results

Assessment of Adrenergic-Deficient Embryonic Heart Rates In Vivo
To gain insight into how adrenergic deficiency leads to embryonic heart failure
and death in utero, we used high-resolution ultrasound imaging to evaluate cardiac
performance in adrenergic-deficient (Dbh-/-) and adrenergic-competent (Dbh+/+ and
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Dbh+/-) embryonic mouse hearts in vivo. Example images from this analysis are
shown in Fig. 4 where sagittal views of an E10.5 mouse illustrate the ability to detect
cardiac contractions and measure crown-rump length as an estimation of embryonic
age. Heart rates were assessed on E9.5, E10.5, and E11.5. Embryos were then
collected for genotyping and genomic expression analyses as described in the Materials
and Methods section. No significant differences were observed in mean heart rates
from adrenergic-deficient mouse embryos compared to controls at any of these ages
(Fig. 4 C).
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Figure 4. Embryonic ultrasound imaging depicts crown,heart, and rump of E10.5
embryos in live dams (A and B). Heart rates were measured at midgestation to
determine embryo viability (C). Attrition rates were calculated based on detection of
heart beat at the various stages of development.
It is important to note, however, that we only measured heart rates from embryos
that were alive, and thus did not factor in zeros for those hearts not beating at the time
of isolation. Overall attrition rates were similar between genotypes at E9.5 and E10.5,
but increased dramatically in the Dbh-/- group at E11.5, with roughly half of the
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adrenergic-deficient population not surviving by this stage of development (Fig. 4D).
These findings are consistent with the original reports about these mice showing that
most Dbh-/- mice survive through E10.5, but then steadily decline in numbers over the
next few days with >80% dead by E15.5 in heterozygous (Dbh+/-) dams [11]. It
appears that the Dbh-/- embryos have nearly indistinguishable heart rates compared
with their adrenergic-competent counterparts in utero until shortly before their demise.
Since we recorded heart rate information from the same sets of embryos on successive
developmental days, we were able to witness this phenomenon directly. In some
cases, heart rates would appear essentially normal for all genotypes at E9.5, E10.5, and
E11.5, but occasionally we would see some of the hearts that were beating well at E9.5,
E10.5, or even E11.5, begin to develop slow, labored contractions sometimes with
associated asynchronous and arrhythmic activity. In other cases, the slow labored
irregular contractile activity first appeared at E11.5 or E12.5, typically followed by death
within 24 hrs. Consequently, it appears that beating rates develop normally during the
early phase of heart development, but then start to decline beginning around E10.5 in
some Dbh-/- hearts but not in others. There appears to be a window that extends for a
few days where the heart is vulnerable to the absence of adrenergic hormones, but this
does not always become evident until several days after E10.5.
We took advantage of this observation by using the echocardiographic
assessments to identify viable hearts of various genotypes (Dbh+/+, Dbh+/-, and Dbh-/-)
that were beating at normal physiological rates. The hearts were then collected
immediately following echocardiography for analysis of gene expression differences
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between adrenergic-competent and adrenergic-deficient embryonic mouse hearts at
E10.5, near the beginning of the developmental period where embryos show greatest
vulnerability to adrenergic deficiency [10, 11]. The objective of this experiment was to
determine if there were underlying alterations in gene expression profiles that precede
the physiological decline and ultimate death of Dbh-/- embryos in utero. The larger goal
of this study was to determine how adrenergic signaling plays an essential role during a
critical period of embryonic heart development. To minimize confounding variables
related to downstream gene expression changes incurred as a consequence of heart
failure in general, we sought to obtain early specimens that were asymptomatic. The
criteria that we used included assessment of heart rates, crown-rump lengths, and
general morphological/structural appearance at time of dissection. The embryos that
we collected for this analysis were indistinguishable from each other in terms of these
criteria and all appeared to be in relatively good health at the time of isolation at E10.5.
Genomic Assessment of the Adrenergic-Deficient Embryonic Heart
We thus identified four viable Dbh-/- experimental and four Dbh+/+ control ageand size-matched E10.5 mouse hearts for the microarray analysis. To assess changes
in gene expression between these two groups, we extracted RNA and analyzed the
samples using Mouse Genome 430A 2.0 Arrays (Affymetrix®, Santa Clara, CA). These
arrays permit simultaneous evaluation of > 22,000 annotated genes in the mouse
genome. The microarray data were initially analyzed using the Affymtrix® MAS5.0
software. This yielded a list of 22 genes that were significantly (p < 0.05) altered by a
factor of two or more between E10.5 Dbh-/- and Dbh+/+ hearts (Table 2).
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Table 2. Genes determined to be significantly altered on microarray by Gene Logic
analysis (P ≤ 0.05).

Nine of these genes were down-regulated in Dbh-/- hearts relative to Dbh+/+
hearts, with the retinoic acid biosynthetic enzyme, beta-carotene 15,15‟21

monooxygenase (Bcmo1) and phospholipase A2, group IID (Pla2g2d) genes displaying
the greatest decreases (-2.7-fold). Thirteen genes showed strong increased
expression, with fibroblast growth factor 20 (Fgf20) commanding the greatest increase
(+5.3-fold). One gene, fibromodulin (Fmod), was identified twice (from two different
target sequences on the array) as a gene displaying increased expression (+2.2-fold
and +2.7-fold) in the adrenergic-deficient hearts.
Secondary analysis of the entire data set using a filtration algorithm generated a
list of 114 genes that showed high probability of mRNA transcript presence and a
statistically significant (p ≤ 0.05) change of mean expression between Dbh-/- and
Dbh+/+ samples. A flow-chart outline of the criteria used for this analysis is provided in
figure 5.
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Figure 5. Algorithm designed to identify genes having a consistent and significant
change in gene expression.
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Table 3. List of 21 genes determined to be significantly altered after the S.A.M. 3.0
analysis.

This method generated a list of genes that showed a lower fold-change (≤ 2-fold) than
that found in the MAS 5.0 analysis, but showed greater consistency in signal detection
among each of the 4 samples within the Dbh-/- and Dbh+/+ groups. These genes were
then analyzed using the publicly available significance of microarray analysis 3.0 (SAM
3.0) method [41]. This methodology generated a list of 21 significantly altered genes
(Table 3).
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Only one of the genes identified by the SAM 3.0 analysis was found in common
with the initial MAS 5.0 analysis, and that was Fmod, which displayed a 1.7-fold
increase in Dbh-/- hearts relative to Dbh+/+ control hearts. As with many genes, Fmod
is represented multiple times on the array, and three of the six Fmod target sequences
on these arrays were identified as showing significantly elevated expression levels in
the Dbh-/- hearts when analyzed by either the MAS 5.0 or SAM 3.0 methods. From the
SAM analysis, Fmod expression showed the greatest enhancement in Dbh-/- hearts
relative to Dbh+/+ hearts, while the leukemia inhibitory factor receptor (Lifr) showed the
greatest decline (-2.0-fold) (Table 3).
Many interesting and unexpected gene expression changes were found from
both of the analysis methods employed here. Before proceeding to analysis of
individual genes, we first looked at the types of changes that occurred as a result of the
absence of adrenergic hormones in these E10.5 mouse hearts by evaluating the
distribution of broad categories of gene expression changes observed from the MAS 5.0
and SAM 3.0 methods. As shown in the pie-charts depicted in figure 6, genes involved
in metabolism and signal transduction combined for over half the total number of
significant changes observed using either method. Other categories of genes showing
significant differences were those involved in transcription (e.g., Ebf2, Zfp191, and
Zim1), transport (e.g., Cacna2d2, Kcnj6, C1qI3, and Nkiras1), and extracellular matrix
or cell structure (e.g., Fmod, Pcdhac2, Mgp, Cttn, and Pign), as well as several genes of
unknown function.
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Figure 6. Distribution of genes called significant on GeneLogic and S.A.M. 3.0
analyses. The data shown here is distributed by gene ontology.

RT-PCR Validation and Assessment of Microarray Data
To verify expression changes observed from the microarray analyses, we
selected specific candidate genes from those listed in Tables 2 and 3 for quantitative
mRNA analysis using real-time PCR (RT-PCR). Because Fmod was consistently found
to be elevated by both microarray data analyses, this was one of the targets chosen.
Another gene that appeared to be a good candidate for further study was the
neurofibromatosis 1 (Nf1) gene because targeted disruption of this gene has been
shown to lead to embryonic lethality due to heart failure during a similar stage of
embryonic development in mice [42]. Although there does not appear to be another
single gene from the microarray analyses (Tables 2 and 3) that has been identified to
cause similar embryonic lethality when knocked out or over-expressed, there were
several genes found to be important in the synthesis of retinoic acid, notably including
Bcmo1 [43] and Retinol dehydrogenase 12 (Rdh12) [21]. In addition, we also included
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the aldehyde dehydrogenase 1A2 (Aldh1A2, also known as Retinaldehyde
dehydrogenase 2, Raldh2) gene, because this is an essential retinoic acid biosynthetic
gene during early heart development [44]. The Retinol-binding protein 1 (Rbp1) was
also included in the analysis since expression of this gene is often used as a surrogate
for evaluating retinoic acid concentrations because its expression levels typically reflect
changes in retinoic acid concentrations in the tissue being examined [45].
Fmod expression appeared similar when evaluated either by microarray or RTPCR. In contrast, there was not good correlation between the microarray and RT-PCR
results for Nf1. We tested two different sets of primer sequences specific for the Nf1
gene, but neither showed much similarity to the microarray results for this gene.
Bcmo1, on the other hand, displayed strong down-regulation in Dbh-/- hearts regardless
of whether it was analyzed using the microarray or RT-PCR results (Figure 7). This
experiment was repeated several times with independent mRNA samples, and we
always obtained similar results indicating strong down-regulation of this gene in E10.5
Dbh-/- mouse hearts relative to Dbh+/+ control hearts. The Aldh1A2 and Rbp1 genes
each displayed nearly 2-fold increased expression in Dbh-/- hearts from the microarray
data, and both were corroborated by the RT-PCR data to varying degrees. In the case
of Aldh1A2, only a relatively slight increase in expression was observed from the RTPCR results, whereas Rbp1 displayed comparatively more robust expression when
measured by RT-PCR (Figure 7).
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Figure 7. Validation of Microarray data. (A) RNA from the same hearts used for the
microarray experiments was utilized to validate the experiment using RT-PCR. (B) The
results showed a good correlation between methodologies. Of the genes probed, 5 of 8
or 62% showed similar changes in gene expression.
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Retinoic Acid Concentration Assessment
These results indicated that retinoic acid synthesis may be perturbed in
adrenergic-deficient E10.5 mouse hearts, but it was not initially clear if this was true
because one biosynthetic enzyme gene, Bcmo1, was strongly down-regulated in the
absence of adrenergic hormones while expression of the primary retinoic acid
biosynthetic enzyme gene, Aldh1A2, appeared to be up-regulated. The increases in
Rbp1 expression also indicated that RA may be increased in adrenergic-deficient E10.5
hearts.
Consequently, we decided to examine expression of several other genes thought
to play important roles in RA synthesis, transport, and metabolism. The expression
profiles for several of these genes are shown in Fig. 8. From these data, it is clear that
only Bcmo1 is down-regulated in the absence of endogenous adrenergic hormones
(Dbh-/-), while most of the rest of the RA-related genes analyzed here showed
increased expression in E10.5 Dbh-/- mouse hearts relative to control Dbh+/+ hearts.
Earlier studies have shown that Bcmo1 expression is down-regulated in response to
elevated tissue RA concentrations, suggesting a possible feedback inhibition
mechanism for expression of Bcmo1 [22].
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Figure 8. Microarray gene expression profile of several enzymes involved in the
synthesis and metabolism of retinoic acid. A comparative analysis of Dbh-/- mouse
model to adrenergic competent controls (n=4).
To determine if tissue RA concentrations were actually altered in adrenergicdeficient embryos, we employed a sensitive bio-assay using the previously described
F9-RARE-LacZ cell line [46, 47]. This cell line produces the galactosidase (gal)
reporter gene under the control of a promoter that is exquisitely sensitive to RA
concentrations, and hence, gal output is directly proportional to the concentration of
RA present. Thus, a standard curve was generated using known concentrations of RA
(Figure 9A) thereby enabling measurement of RA in extracts from individual E10.5
mouse embryos applied directly to the cultured cells. The results show that RA
concentrations were significantly (p < 0.05) elevated by an average of > 3-fold in
adrenergic-deficient hearts compared to adrenergic-competent controls (Figure 9 B and
C).
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Figure 9. Evaluation or RA concentration in embryonic tissue. A standard curve was
generated to establish a detectable limit for the F9 RARE cell bioassay (A). RA
concentration was measured in embryonic trunk extracts of adrenergic competent and
adrenergic deficient embryos (B and C).

Discussion

The importance of adrenergic hormones in the embryonic mouse heart is evident
as mice lacking the ability to synthesize NE and EPI begin to die in utero at E10.5, and
very few survive to E13.5 [11]. To elucidate the mechanisms which lead to the
embryonic cardiac failure of the Dbh-/- mice, we collected E10.5 hearts from Dbh-/embryos which showed no obvious signs of cardiac distress. The hearts were first
analyzed using high resolution ultrasound, to access viability and heart rate. We then
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selected only those mice with comparable heart rates to Dbh+/+ mice for microarray
analysis of gene expression.
The microarray analysis was predominately a two part analysis. A standard
basic analysis and a more detailed analysis which took into account mathematical
skewing. The basic analysis was conducted by Gene Logic which separated out genes
showing a 2-fold average change in expression and a student T-test significance of p ≤
0.05. The result of this analysis yielded 23 altered genes, which is less than 1% of the
total genes assayed on the microarray chip. These highlighted genes belonged to
many different categories of cellular function, such as; signal transduction, metabolism,
extra cellular matrix components, gene transcription and protein transport. To highlight
genes having a consistent and significant differential expression across each sample
set, we developed an algorithm that would generate a list of genes that were expressed
above the background noise of the assay and consisted of signal values which could be
compared to one another equivalently. When we compared the results of the S.A.M.
3.0 analysis to that of the MAS5.0 analysis, we found that only fibromodulin showed up
on both list. However, many of the genes on the S.A.M. 3.0 list were associated with
the same pathways seen in the MAS5.0 analysis. Both list of differentially expressed
genes revealed interesting facts about the gene expression profile of the Dbh-/- mouse
heart at E10.5. Collectively, the data suggest genetic alterations of genes involved in
signal transduction and metabolism of the Dbh-/- mouse heart. The altered genes
representing these two ontologies remarkably account for 52 % of the aberrantly
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expressed genes in the Dbh-/- mouse heart. This observation is consistent in both the
MAS5.0 and S.A.M. 3.0 analysis of the microarray data.
When we independently examined genes within associated functional pathways
using real-time RT-PCR, we found changes in gene expression that were consistent
with known pathway associations between those genes. For example, the retinoic acid
synthesis genes Aldh1A2, Bcmo-1, and Rbp-1, showed gene expression changes
consistent with a change in cellular retinoic acid concentration (Figure 10) [48-50].
Others have shown that Bcmo-1 and Rbp-1 have an inverse gene expression
relationship, which we observed in our data [17, 51]. We showed here that retinoic acid
concentration and/or signaling in the Dbh-/- mouse heart is affected as a result. This
also suggests that the adrenergic hormones regulate retinoic acid homeostasis during
embryonic mouse heart development.
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Figure 10. Diagram of RA metabolism and movement in the cell via carrier proteins and
enzymes.

It has been suggested that the loss of adrenergic hormones results in an inability
embryos to respond and survive the chronic hypoxia experienced during development
[14]. It has been shown that embryonic hypoxia induces the release of norepinephrine
[52], which is known to lead to vasodilatation and increased blood flow to overcome
cellular hypoxia. However, the Dbh-/- myocardium cannot release NE and would
therefore endure fatal degrees of hypoxia. It is well known that Vegf-A and Hif1α are
robustly expressed under conditions of hypoxia [53], and would be differentially
expressed in the Dbh-/- mouse heart if the heart were failing due to hypoxia. Our data
show that the gene expression of Vegf-A and Hif1α in the Dbh-/- heart are not
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significantly different from the Dbh+/+ controls (Figure 11). Portbury et al. 2003,
suggests that NE is essential for acute reversal of bradycardia due to hypoxic conditions
during embryonic development and that the hypoxic conditions can be eliminated thru
oxygen homeostasis [15, 54]. However, our in vivo data indicate that the loss of
adrenergic signaling, specifically NE, does not lead to hypoxic conditions. The lack of
significant change in the expression of these key hypoxia inducible genes indicates that
the Dbh-/- mouse model may not be susceptible to hypoxic injury due to the loss of
adrenergic hormones. But, suggest that the Dbh-/- mouse heart does not suffer from
chronic hypoxia anymore than the Dbh+/+ littermates.

Figure 11. Vegf-A expression during midgestation is unaltered in the embryonic mouse
heart. Evaluation of the gene expression of Vegf-A in the Dbh-/- mouse heart or a three
day period during midgestation shows no significant difference in the level of expression
vs. the Dbh+/+ heart at E9.5, E10.5, or E11.5 (n=3,3, and 6).
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The gene expression changes observed in the Dbh-/- mouse hearts reveal gene
ontology‟s in five different categories. Interestingly, 52 % of the altered genes fall into
two categories; signal transduction and cellular metabolism. We found that Rdh-12, a
short chain dehydrogenase responsible for the oxidation and/or reduction of all-trans
retinoids had up-regulated gene expression in the Dbh-/- mouse heart. Rdh-12 can
convert retinol to retinal, or reduce retinal to retinol [21]. These metabolites are the
precursor of retinoic acid; therefore, this could indicate that the Dbh-/- mouse may have
an altered synthesis of retinol or retinal leading to altered retinoic acid synthesis [55]
[56].
Another differentially expressed gene involved with retinol availability is Rbp-1.
Rbp-1 is expressed widely in the developing embryo and plays a role in sequestration
and delivery of retinol to cells for conversion to retinoic acid or storage [57, 58]. The
Dbh-/- mouse heart shows a 2 fold increase in the expression of Rbp-1 determined by
real-time RT-PCR. This finding also suggest an excess of cellular retinoic acid since
Rbp-1 has been shown to be a direct target of retinoic acid mediated gene expression
[45].
Bcmo-1 is responsible for the conversion of beta carotene to retinal in the
biosynthesis pathway of retinoic acid [59]. Bcmo-1 was significantly down regulated in
the Dbh-/- mouse heart. This finding suggests either a down-regulation by retinoic acid
or an insufficient activation of Bcmo-1 gene expression. Studies have shown that
Bcmo-1 is a direct target of retinoic acid in a negative feedback system [51, 60]. These
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findings along with other supportive data indicate an increase in the concentration of
retinoic acid in the Dbh-/- mouse model.
When we examined the concentration of retinoic acid in the Dbh-/- mouse heart,
we found a significantly higher concentration in the Dbh-/- mouse hearts as compared to
the Dbh+/+ controls. This indicates that the E10.5 Dbh-/- mouse heart does not
maintain retinoic acid homeostasis at E10.5 like their Dbh+/+ counterparts. This is a
major finding since it has been well documented that an excess of retinoic acid during
embryonic development can lead mid-gestational embryonic lethality [61-63].
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CHAPTER 3 DISTINCTIVE LEFT HEART CONTRIBUTION OF
ADRENERGIC-DERIVED CELLS

Introduction

Cardiac development is a multifarious process that involves cell specification,
determination, patterning, migration, and growth. This is achieved through precise
regulation of gene expression within several cell types during embryonic development.
The production of signaling molecules designed to coordinate these events during
embryonic development is crucial. Among the multitude of signaling molecules are the
adrenergic hormones, adrenaline and noradrenaline. Molecular studies of the function
of adrenergic hormones during embryonic development have shown that they are vital
for cardiac development because mice lacking adrenergic hormones die in utero near
midgestation due to apparent heart failure [11].
Adrenergic cells are distributed throughout the developing heart, including
regions associated with pacemaking and conduction tissue [64, 65]. In mice, cardiac
adrenergic cells appear as early as embryonic day 8.5 (E8.5), and remain in the
developing heart through neonatal stages of development [12]. These cells are
responsible for the production and secretion of adrenaline and noradrenaline [64-66].
Immunohistochemical staining experiments for adrenergic biosynthetic enzymes,
including tyrosine hydroxylase (Th), dopamine -hydroxylase (Dbh), and
phenylethanolamine n-methyltransferase (Pnmt), indicated transient expression of an
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adrenergic cellular phenotype in different regions of the heart as development proceeds
[37, 65].
Most of the anatomical work with adrenergic cells in the heart has focused on
adrenal chromaffin-like cells that are commonly found in “glomus-like clusters” in and
around cardiac ganglia from a wide variety of species [67-73]. More recent work
suggests that adrenergic cells are also found in a subset cardiomyocytes [12, 66, 74].
Indeed, Pnmt enzymatic activity and adrenaline are found in both cardiac atria and
ventricles from rats [75-79], mice [78], and humans [80-82]. Further, Pnmt activity
increases dramatically following chemical denervation with 6-hydroxydopamine (6OHDA), indicating that it is likely expressed in non-neuronal tissue within the heart [83,
84]. The precise anatomical localization of Pnmt-expressing cells within the cardiac
atria and ventricles has not been described previously.
In the present study, we explore the distribution of adrenergic-derived cells within
the adult mouse heart. To accomplish this objective, we used the previously
established Pnmt-Cre mouse model, in which the Cre-recombinase gene was knockedin to the Pnmt gene locus. When crossing Pnmt-Cre mice with ROSA 26 reporter
(R26R) mice [85], the β-galactosidase (βGAL) reporter gene was exclusively activated
in adrenergic (Pnmt-expressing) cells [12, 86]. It is important to note that cells marked
by βGAL expression in this model reflect distribution of cells that are derived from an
adrenergic lineage even if they no longer actively express Pnmt and the other
adrenergic enzymes [66, 74]. We utilized standard histological staining techniques
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combined with computer-aided three-dimensional reconstruction to provide a detailed
anatomical characterization of the fate of adrenergic cells in the adult mouse heart.
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Methods

Materials
All chemicals and reagents were obtained from Sigma-Aldrich (St. Louis, MO)
except where noted otherwise.
Mice
The Pnmt+/Cre and ROSA26+/βgal (R26R) mice have been described previously
[12]. The Pnmt+/Cre mice were derived after several backcrosses (4-6) with wild-type
129/SvJ mice (stock # 0006910;Jackson Laboratories, Bar Harbor, ME), and the R26R
line was backcrossed with wild-type C57Bl/6 mice (stock #000664; Jackson
Laboratories, Bar Harbor, ME) for a similar number of generations (4-6). Each strain
was then independently maintained in homozygous condition (PnmtCre/Cre and
ROSA26βgal/βgal, respectively) in the Transgenic Animal Facility at the University of
Central Florida where they were housed on a 12:12h light:dark cycle and provided with
food and water ad libitum. For all experiments described here, PnmtCre/Cre and
ROSA26βgal/βgal mice were mated, and the resulting heterozygous offspring were
studied. All animal experiments were conducted in accordance with the University of
Central Florida Animal Care and Use Committee, consistent with regulations for
vertebrate animal research outlined by the National Institutes of Health (NIH). The
protocol (#08-32) was approved by the University of Central Florida Animal Care and
Use Committee on August 18, 2010. This approval has been renewed annually since
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the initial approval date of August 24, 2008. The title of the protocol is “Molecular
imaging of novel cardiomyocyte stem cells”, and it is active through August 17, 2011.
Histological Preparation and Staining
Adult (8-10 weeks of age) Pnmt+/Cre ROSA26+/βgal mice were anesthetized with
2.5% isolflurane and sacrificed by decapitation while under full anesthesia. The heart
was rapidly removed and perfused retrogradely via a cannula positioned in the aorta.
After flushing with phosphate-buffered saline (PBS), the heart was fixed by gentle
perfusion with 20 mls of 2% paraformaldehyde in PBS followed by immersion in the
same solution for an additional 24h at 4oC. The hearts were then transferred to a
solution of 30% sucrose containing 0.02% sodium azide in PBS for at least another 24h,
until ready for cryostat sectioning. The hearts were then embedded in Tissue-Tek®
freezing gel (EM Sciences, Hatfield, PA) for sectioning using a Microm HM 505 N
cryostat set to a temperature of -26°C to -28°C. The hearts were cut at 14-20 microns
and mounted onto Super-Frost Plus microscope slides (Fisher Scientific, Inc.,
Pittsburgh, PA). Tissue sections were stained immediately or stored at 4°C for
subsequent use.
β-galactosidase activity
Tissue sections were stained for β-galactosidase activity using 50mM XGAL
dissolved in dimethylformamide as described previously [12]. XGAL was then diluted in
XGAL staining buffer solution (5mM potassium ferricyanide, 5mM potassium
ferrocyanide, 1mM MgCl2, and .01% Tween-20 in PBS) at a dilution factor of 1:39.
Slides were rinsed in PBS for 10 mins and incubated in the diluted XGAL solution
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overnight at 37°C. The following day, the slides were washed in PBS 3 times for 10
mins each. Sections were counterstained with eosin followed by ethanol dehydration
and clearing in xylene for 10 mins before adding a coverslip using Permount (Fisher
Scientific, Inc., Pittsburgh, PA). Low-magnification digital images of histology sections
were obtained using a Leica MZ16A stereomicroscope and Leica DFC 320 camera
system. Higher magnification images were acquired using an upright Nikon Eclipse
E600 light microscope with attached SPOT RTTM Slider camera (Diagnostics
Instruments, Inc., Sterling Heights, MI).
Immunostaining
For immunofluorescent staining experiments, the tissue was prepared as above,
and stored at -20oC until use. The general staining procedure was performed as
previously described [3], with some modifications as indicated in the following text. The
slides were then thawed, heat-dried at 37oC for 2 minutes prior to permeabilization in
0.1 N HCL at room temperature for 5 minutes followed by a single wash with tap water.
The sections were then incubated in PBS containing 10% Tween 20 for 6 hours
followed by two 15-min washes in PBS without Tween 20. Blocking was performed by
incubating in PBS containing 5% fetal bovine serum (Hyclone Labs; Logan, UT) for 30
minutes prior to incubation for 2 hours at 37oC in a humidified chamber with a rabbit
anti-Pnmt primary antibody (AB110) from Millipore, Inc. (Temecula, CA) at a dilution of
1:250 in PBS. In some experiments co-staining with a mouse anti-sarcomeric -actinin
(A7811, Sigma-Aldrich; St. Louis, MO) at a dilution of 1:100 in PBS was also performed.
The sections were then washed twice with PBS alone for 15-min each, followed by 30-
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min incubation with a FITC-conjugated donkey anti-rabbit IgG (Jackson Immunolabs,
Bar Harbor, ME) and/or an Alexa Fluor 594-conjugated goat anti-mouse IgG (Invitrogen,
Inc.; Carlsbad, CA). The sections were again washed with PBS as above, then dried
and cover-slipped for fluorescent microscopy.
2D Digital Image Analysis
Images were analyzed using Adobe Photoshop™ software. For βGAL
quantification, the size of the pictures was adjusted to 669300 pixels (690 x 970 pixels)
per image. This adjustment was confirmed with the image histogram option in the
Photoshop software. Once all images were set to the equivalent size, we used the
Photoshop “magic wand” to select all blue staining from the left, and then the right side
of the heart. Histogram analysis of the βGAL staining on the left and the right side of
the heart yielded a total number of blue pixels for each side of the heart. The average
pixel value for each individual heart was derived from analysis of 5-10 random sections.
3D Image Reconstruction
For a series of 2D slices of the stained heart, we applied a color-based clustering
technique to segment regions of interest (i.e., XGAL-stained regions) and then
reconstructed the corresponding 3D volume. Among all of the 2D slices, a subset of
slices of interest can be manually selected according to different experiential goals. The
segmentation for each selected slice went through three steps. First, a slice was
converted into the L*a*b* color space. Next, the k-means algorithm was employed using
squared Euclidean distance to cluster the color feature of the slice into several clusters,
where each cluster corresponds to a different color range. Note that the number of
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clusters, K, is experimentally determined for each slice in view of the intensity
inhomogeneity among the slices. While K is initialized for each slice by 6, it can be
interactively tuned (increasing or decreasing) in order to find the optimal segment that
corresponds to the XGAL-stained regions the best. Then, the optimal segment is
extracted according to the labeling index of the corresponding cluster. Repeating the
above steps to each slice, we obtained respective XGAL-stained regions for all of the
slices of interest. Subsequently, a rigid registration (i.e., translation and rotation) are
applied to align the segments obtained from different slices. After that, the aligned
segments are sequentially stacked for 3D volume reconstruction. Note that In order to
simulate the thickness of a slice, the segmented XGAL-stained regions of each slice are
repeatedly stacked for 7 times. The stacked 3D data are saved in MetaImage format
(.mhd). Finally, we utilized a free tool called ITK-SNAP
(http://www.itksnap.org/pmwiki/pmwiki.php) to load the 3D data and construct the 3D
shape of the XGAL-stained volume. ITK-SNAP provided 2D views from axial, sagittal,
and coronal directions as well as 3D visualization of the volume that can be observed
from dynamic viewpoints.
Statistical Analyses
All data are presented as the Mean ± S.E.M. Statistical significance was
evaluated using the Student‟s T-test, with P < 0.05 required to reject the null hypothesis.
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Results
To identify adrenergic-derived cells in the adult mouse heart, we first set up
matings between PnmtCre/Cre, ROSA26+/+ and Pnmt+/+, ROSA26βgal/βgal as previously
described [12]. The offspring from these matings were allowed to develop normally until
adulthood (8-10 weeks), at which time they were sacrificed, and the hearts collected for
histological staining analyses. In this model, cells that express βgal are indicative of
cells that are derived from an adrenergic lineage due to their expression of Crerecombinase from the Pnmt genetic locus. βgal expression is readily visualized as blue
cells following XGAL histological staining. Examples of this staining are shown in a
series of representative adult heart sections in figure 12.
Adrenergic-derived cell distribution in the adult mouse heart
XGAL+ cells were observed in several regions of the myocardium. For example,
some of the most strongly positive XGAL staining was consistently observed in the left
atrium (LA); thereby indicating that many of the myocytes in the LA were derived from
an adrenergic lineage. The left ventricle (LV) was also stained heavily with XGAL in an
apparently non-random and non-uniform pattern. In sections from the ventral surface of
the heart, we saw an area of strong XGAL+ staining near the apex (Figure 12a), but as
we progressed from ventral towards more dorsal sections, the LV staining pattern
appeared to shift first to a more medial location along the longitudinal axis of the heart
(Figure 12, panels b and c), and then continued to shift towards the base of the heart
(Figure 12, panels d-f). In addition, the XGAL staining pattern seemed to generally
redistribute from the periphery towards a more interior position when moving from
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ventral to dorsal locations (Figure 12, panels b-f). XGAL staining of the papillary muscle
(PM) was primarily localized to the superior border, with minimal staining at the right
base of the muscle (Figure 12, panels b and c). XGAL+ staining of the PM was
unchanged as the sections were analyzed from ventral to dorsal views. No XGAL+
staining was observed in endothelial cells lining the aorta, pulmonary trunk, or cardiac
vessels.
The interventricular septum (IVS) showed intermediate levels of XGAL+ staining
with a preferential tendency for localization in the right side of the septum (Figure 12,
panels b-f). This pattern of staining was observed throughout the entire depth of the
heart. As seen in figure 12, the XGAL+ staining in the body of the IVS was sparse
throughout the heart however, we observed a small concentrated cluster of XGAL +
cells along the basal crest of the IVS (Figure 12, panels d-f). The right ventricular free
wall (RVFW) had minimal XGAL+ staining in most sections of the adult mouse heart
(Figure 12, panels a-f). Notably, however, XGAL+ staining in the RVFW was localized
to two small areas, one near the apex and another near the base (Figure 12, panels g
and h). Additionally, whole mount staining of the adult mouse heart reveals the same
unique pattern (Figure 12, panels i-k). These results were consistent in each of the
adult mouse hearts analyzed, thus suggesting that while adrenergic-derived cells are
primarily localized on the left, there are smaller contingencies of these cells in the IVS
and RV.
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Figure 12. Adult mouse heart showing the distribution of Pnmt expressing cells. 2D
slices show how PNMT expressing cells penetrate the depth of specific regions of the
left ventricle (LV), and nearly fill the left atria (LA) (A-H). Whole mount staining shows a
3 dimensional surface view of the PNMT expressing cells (I-K).

Quantification of XGAL+ staining in the adult mouse heart
To quantify the XGAL+ staining of the adult mouse heart, we analyzed the total
XGAL+ cells in both atria and both free walls of the ventricles. To do this, we first
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demarcated the major sections of the heart and created a right/left line of separation
(Figure 13). We then quantified blue pixels in images of random sections from each
heart. Multiple sections were analyzed from three different hearts, and the results are
summarized in Table 4. The combined results show that on average, 89% of XGAL+
cells were found on the left side of the heart. As a negative control, we quantified
XGAL+ staining in hearts resulting from Pnmt+/+ROSA26βgal/βgal x Pnmt+/+ROSA26+/+
matings (Figure 13, panels c and d). As expected, no XGAL+ staining was observed in
these control hearts. These results demonstrate that XGAL+ staining was
predominantly, though not exclusively, present in the atria and ventricular chambers of
the left myocardium in the adult mouse.
Table 4. Quantification of XGAL+ staining in the adult mouse heart after right/left
demarcation.
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Figure 13. To quantify Pnmt expression, Pnmt+/Cre, ROSA26+/βgal adult mouse heart
images were partitioned into right and left heart. The line of separation originates from
the apex and extends toward the base of the heart and through the aorta (bold line).
Additional partitioning isolates the IVS from the RVFW and LVFW (panel b and d).
Each partition was then analyzed to determine the total pixels containing the blue
XGAL+ stain. The left heart shows heavy XGAL+ staining when compared to the right
side of the heart. Pnmt+/+, ROSA26βgal/βgal control heart shows no XGAL+ staining
(panel c and d).
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3D computer-aided reconstruction of the PNMT expressing cells in the mouse heart
To gain a more complete view of adrenergic cell contributions in the adult mouse
heart, we examined the three-dimensional distribution of XGAL+ cells in this model
utilizing customized computer algorithms to generate three-dimensional representations
of the XGAL staining patterns in the adult mouse heart. Representative static views of
this analysis are shown in Figure 14. The XGAL staining in the adult mouse heart
appears to be largely restricted to the left side of the heart, with greater concentration
near the base and mid-regions of the LV compared to the apical region. These threedimensional views confirm the two-dimensional analyses already shown, and provide a
more thorough picture of the XGAL staining distribution throughout the adult mouse
heart.
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Figure 14. Three-dimensional reconstruction of the XGAL+ staining in the Pnmt+/Cre,
ROSA26+/βgal heart. (a) Representative two-dimensional section of the adult mouse
heart were cut at 20 microns. (b) Still-shot of a 3D-rendered image generated from
stacked 2D images as described in the methods section. The arrows point to equivalent
regions in both panels that roughly correspond to basal, mid, and apical concentrations
of XGAL+ cells in these hearts. Please see online supplemental figures 1 and 2 for
different perspective views of the 3D image analysis for these data.

Histochemical and immunofluorescent analyses of adrenergic-derived cells in the adult
mouse heart
To obtain a more detailed view of the XGAL+ staining in the adult mouse heart,
we captured microphotographs of increased magnification. Representative examples of
these results show that most of the cells in the LA were stained with XGAL, especially
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along the peripheral borders. Similarly, the free wall of the LV was also stained strongly
for XGAL (Figure 15, panels d-f).

Figure 15. Pnmt-Cre expression in cardiomyocytes of the adult mouse heart.
XGAL+ staining in the left heart reveals the anatomical location of cells which have
historically expressed the Pnmt gene. Pnmt expression can be seen in the LA and the
apical border of the LV ( panel a). Pnmt expression is seen distributed throughout the
LA and can be seen within the cardiomyocytes under higher magnification (b, c). Pnmt
expression is also observed in the free wall of the LV and appears to be within the
cardiomyocytes, based on anatomical and morphological characteristics (d-f).

Anatomical and morphological evaluations of the sections are consistent with a
myocyte-specific pattern of staining, though it is also clear that many myocytes remain
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unstained. Examples of specific myocardial staining were verified with higher
magnification phase-contrast and light microscopic images (Figure 16 a and 16 c).
Inverted image analysis of the stained cells where characteristic sarcomeric striations
are clearly evident in the XGAL-stained cells (Figure 16 b and 16 d, arrows). In
addition, we combined XGAL staining with immunofluorescent labeling of myocardial
cells using an anti-sarcomeric -actinin antibody (Figure 17). These results clearly
show overlapping staining for XGAL and the myocyte marker protein, sarcomeric actinin (arrows), thereby confirming that Pnmt-driven XGAL+ staining is found in adult
cardiac myocytes in the mouse heart.
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Figure 16. High-magnification phase-contrast and light microscopy images of XGALstained cells in the LV free wall from an adult mouse heart. (a) Black and white phasecontrast image of XGAL-stained myocytes (arrows). (b) Color light microscopy image
of an XGAL-stained myocyte (arrow). Inverse images of (a) and (b) are shown in
panels (c) and (d), respectively. Note the characteristic striated rectangular-like shape
of the stained cells.

In this model, XGAL+ staining demarcates active as well as historical expression
of Pnmt [12]. To identify cells actively expressing Pnmt in the adult mouse heart, we
used an anti-Pnmt antibody to perform immunofluorescent labeling of cardiac tissue
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sections from adult Pnmt+/Cre,ROSA26+/βgal mice. We first tested the specificity of this
antibody using adult adrenal gland sections from the same mice.

Figure 17. Co-localization of XGAL and sarcomeric α-actinin in LV cells of the adult
mouse heart. Immunofluorescent staining for sarcomeric α-actinin in the adult mouse
LV shows characteristic striations associated with cardiomyocytes (a, arrows). An
indicating a history of Pnmt gene expression (b, arrows). Overlay of the
Immunofluorescent and XGAL staining show a clear co-localization of cells that have a
history of Pnmt expression and cells with a cardiomyocyte phenotype (c, arrows).
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As shown in figure 18, cells in the adrenal medulla were brightly labeled with the
anti-Pnmt antibody, while the surrounding cortex displayed only background
fluorescence (panel a). At higher magnification, the Pnmt immunofluorescent labeling
showed characteristic cytoplasmic localization (Figure 18, panel c), as expected based
on earlier immunofluorescent labeling of adrenal chromaffin cells with different antiPnmt antibodies used in previous studies [65, 86]. When applied to cardiac tissue,
Pnmt immunofluoresent staining identified small triangular-shaped cells that primarily
appeared to be located in interstitial spaces (Figure 18 b, arrows). The labeling also
appeared to be largely cytoplasmic, and was likely not due to autofluorescence since
little or no fluorescent signal was apparent from them upon switching to a red filter
(Figure 18 d, arrows). As an additional control, no specific fluorescent staining of either
adrenal or cardiac tissue sections was observed in the green spectrum in the absence
of the anti-Pnmt primary antibody (not shown). These data indicate that the observed
Pnmt immunofluorescent labeling is specific for cells expressing Pnmt.
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Figure 18. Active Pnmt expression in the adult mouse adrenal glands and heart. The
adrenal gland and heart of adult Pnmt+/Cre, ROSA26+/βgal mice were extracted to
evaluate the distribution of active Pnmt expression. Cryosections of the mouse adrenal
gland were immunofluorescently stained to identify Pnmt expression (green). The
adrenal medulla (Med) showed bright positive staining as expected, while the cortex
(Ctx) of the adrenal gland showed only background fluorescence (a). High
magnification images of Pnmt immunofluorescent staining in the LV reveals small cells
positive for cytoplasmic Pnmt expression in the heart (b, arrows) and adrenal medulla
(c). Negative control for the LV image shown in panel b illustrates the absence of
fluorescent signal in the red spectrum (d).
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To explore this further, we evaluated Pnmt immunofluorescent staining in
different regions of the heart as exemplified in figure 19. Positive Pnmt
immunofluorescent labeling was found within the muscle layers of all four chambers of
the heart, where most of them displayed the small triangular-shaped appearance
(Figure 19, arrows). Some of these appeared to have process extensions, possibly
suggesting neuronal-like characteristics. In fact, many process-like structures were
observed in almost every section (indicated by asterisks, Figure 19).
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Figure 19. Pnmt is expressed in all chambers of the adult mouse heart.
Immunofluorescent staining in the adult mouse heart using an anti-Pmnt antibody
shows active expression in both right and left atria (a-c). The majority of fluorescently
labeled cells (green) in the atria have a triangular-shaped appearance (arrows) with
neuronal-like extensions (asterisks). In addition, cardiomyocyte-like cells also show
positive Pmnt staining (arrowheads) which appears to be cytoplasmic while a few cells
show staining along their lateral border (d-f). The ventricular myocardium also
displayed small triangular-shaped cells which were positive for Pmnt expression (e,
arrows).
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In a few cases, positive Pnmt immunofluorescent staining appeared to label
larger brick-shaped cells in a striated pattern consistent with ventricular myocyte
morphological characteristics (Figure 19 e and 19 f, arrowheads). We next performed
co-immunofluorescent staining of adult mouse heart sections with anti-Pnmt and antisarcomeric -actinin antibodies. When examined at high magnification using confocal
laser-scanning fluorescent microscopy, it was clear that the small triangular-shaped
Pnmt-positive (green) cells did not co-label with the larger brick-shaped striated
myocytes in most cases, but rather were found in close association with the myocytes,
typically in the interstitial spaces as shown in figure 20 (panels a and b, arrows). A few
myocytes, however, appeared to also be positively stained for Pnmt, as indicated by the
overlapping Pnmt and sarcomeric -actinin staining observed (Figure 20 c,
arrowheads). These results suggest that Pnmt is actively expressed in cells throughout
the heart, and that a small number of these appear to be myocytes, though the vast
majority of them appear to be non-myocytes.
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Figure 20. High-magnification confocal co-immunofluorescent staining for Pnmt and
sarcomeric a-actinin in adult mouse heart (LV) sections. Pnmt immunofluorescent
staining in the adult mouse heart identifies small triangular-shaped cells (green) (a, b
arrows) within the interstitial spaces. Cardiomyocyte-specific staining for sarcomeric αactinin (red) shows identifiable striations in branching cells. Immunofluorescent costaining with Pmnt and sarcomeric α-actinin shows apparent Pmnt expression within
some cardiomyocytes (c, arrowheads).
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Discussion

In the present study, we showed that cells with a history of expressing the
adrenergic biosynthetic enzyme gene, Pnmt, were present in the adult mouse heart.
This was confirmed by XGAL+ staining in Pnmt-Cre x R26R mice, where staining was
predominantly found in the left atrial and ventricular muscle chambers. While the
pattern of staining in the left atrium was rather diffuse, the distribution of XGAL+ cells in
the left ventricle was clearly localized to specific regions. Notably, XGAL staining was
heaviest in the basal and mid-sections of the left ventricle, and there was a defined
“patch” of strongly stained cells consistently found near midline and apical sections.
Staining was not exclusive to these regions, but they represent the major densities of
adrenergic-derived cells in the adult heart.
It is important to note that the XGAL-stained cells reflect both active and
historical expression of the Pnmt gene in the heart because Pnmt-Cre acts on the R26R
locus to activate GAL expression permanently through genetic recombination [4].
Consequently, XGAL+ cells represent the total conglomeration of cells that actively
express Pnmt at the time of staining and those that had expressed it at some point
earlier in development. Most of the XGAL+ cells in the adult mouse heart appeared to
have myocyte-like characteristics based on their distribution, size, brick/rectangular
shape, striated patterns, and overlapping staining with a well-established myocyte
marker protein, sarcomeric -actinin.
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In contrast, when we exclusively examined active Pnmt-expressing cells using
immunofluorescent histochemical staining methods with a specific anti-Pnmt antibody,
only a relatively small number of the total Pnmt+ cells in the heart appeared to have
myocyte-like characteristics. The vast majority of cardiac cells that were identified by
Pnmt immunofluorescent staining were small, triangular-shaped cells located in close
association with, but clearly distinct from, myocytes. These Pnmt+ cells were found in
all four cardiac chambers where they were most often found in interstitial spaces
between bands of myocardial cells. Several examples of process-like staining were
observed in Pnmt+ cardiac cells suggesting that some of these may be neurons, though
further experiments with additional cell type-specific markers are required to determine
if this is true. It is nevertheless clear, however, that most of the cardiac cells identified
as positive for Pnmt immunofluorescent staining do not appear to be myocytes. These
results thus suggest that much of the XGAL+ staining likely represents historical
expression of the Pnmt gene in addition to cells that are actively expressing Pnmt.
Previous studies have shown that extracts from the LA display relatively high
levels of Pnmt mRNA and enzyme activity compared to the LV [78, 79, 87], and it has
been known for many years that Pnmt and adrenaline concentrations are generally
higher in the atria than in the ventricles [76, 83, 87]. This appears to be true in human
patients as well [80]. Interestingly, there is also evidence indicating that Pnmt gene
expression is differentially regulated in the atria compared to the ventricles [75-78].
Early studies that examined the anatomical localization of putative adrenergic cells
(chromaffin-like or small-intensely-fluorescent “SIF” cells), and found them mainly in the
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epicardium in the glomus or grape-like clusters of extraneuronal cells associated with
cardiac ganglia [67-73]. Subsequent studies have shown that there is also a significant
fraction of Pnmt-expressing cells that are non-ganglionic in both atria [78], and it is well
established that chemical destruction of sympathetic nerves with 6-OHDA leads to
increases in Pnmt expression and adrenaline production in the heart [83, 84]. Taken
together, these previous studies have shown that non-neuronal Pnmt is expressed in
the adult hearts from a number of mammalian species, including humans. Most of this
expression was reported in the atria, especially the LA [78, 79]. Some of this
expression may be derived from the small clusters of chromaffin-like cells found in and
around cardiac ganglia, but the evidence indicates that there must also be a significant
source of these cells that not associated with ganglia in the heart [77, 80]. The data
presented here in combination with previous reports on the origin of adrenergic cells
within the developing heart suggest that a significant fraction of these cells are derived
from myocardial progenitors [12, 66, 74, 78], while others are likely derived from
invading neural crest subpopulations [88, 89].
The present study is the first to demonstrate the cellular distribution of adrenergic
cells in adult myocardium. Previous histological examinations focused on chromaffin or
SIF cells located in and around ganglia on the epicardial surface of the heart [67-70],
but no specific cellular staining for Pnmt was reported. Subsequent studies have
examined Pnmt mRNA, protein, enzyme activity, and adrenaline formation in the heart
[76-78, 80, 83, 84], but all of these studies relied on preparation of extracts from the
heart. Thus, to the best or our knowledge, this is the first report of detailed anatomical
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and histological identification of cardiac cells that express Pnmt and those that had a
history of expressing Pnmt at some point in their development.
Our previous work demonstrated that adrenergic cells were transiently and
progressively associated with regions of the developing heart associated with
pacemaking and conduction system centers [65]. In the adult mouse heart, we
observed a limited pattern of XGAL+ staining in the right atrium, atrio-ventricular
junction, and along the crest and lateral borders of the interventricular septum that are
generally consistent with the expected distribution of pacemaking and conduction
system tissue, but the predominant pattern of XGAL+ staining in the adult mouse heart
was not found in these regions. In further contrast to earlier stages of development (i.e.,
fetal and neonatal) where XGAL+ staining was observed extensively in the muscle cells
of all four cardiac chambers [12], the adult staining pattern of Pnmt-driven XGAL
staining was clearly much more restricted to myocardium on the left side of the heart.
Interestingly, the left-sided patterning of adrenergic-derived cells in the adult
myocardium does not coincide with any known gene expression localization profiles;
however, it appears to share anatomical similarity with the ascending segment of the
helical ventricular myocardial band (HVMB) described by Torrent-Guasp et al. [35, 90].
Although controversial and not universally accepted [91, 92], the HVMB model
describes the directional orientation and intricate looping of myocardium which occurs in
order to form two independent ventricles that function as a single unit. The detailed
looping described in the HVMB model results in a pair of apical left ventricular loops;
ascending and descending, that criss-cross to form a funnel-shaped structure near the
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tip of the apex. The pattern of XGAL+ staining in the apical region of the adult mouse
heart suggests that adrenergic-derived cells could be a component of the ascending
fibers of the HVMB model. Additional experiments are required to test the validity of this
model.
The presence of adrenergic-derived cells within the adult mouse heart could also
suggest involvement of these cells in stress-mediated cardiomyopathies. In particular,
the cardiomyopathy known as Tako-Tsubo or “Broken-Heart Syndrome” involves
hypokinesis or akinesis of the mid and apical regions of the left ventricle during periods
of severe emotional stress [93-96]. Patients with Tako-Tsubo typically have symptoms
that are similar to myocardial infarction (e.g., chest pain, elevated S-T segment on
ECG), but do not display coronary occlusion. Due to the hypokinesis of the mid and
apical regions of the left ventricular muscle these regions “balloon” out when viewed by
echocardiography, lending Tako-Tsubo another alias, “Apical Ballooning Syndrome”
[97, 98]. The underlying causes of this syndrome are not well understood, however, the
main hypotheses that have been put forward all involve adrenergic mechanisms [99102]. Our current findings show that adrenergic-derived cells preferentially populate
specific portions of the LV free wall, thereby suggesting that these cells could play an
important role in the development of certain stress-induced cardiomyopathies such as
Tako-Tsubo Syndrome. It is important to note, however, that possible connections to
clinical syndromes remain speculative at this point, and that additional experiments are
needed to determine the validity of these ideas.

67

In conclusion, this work demonstrates a distinctive and unexpected left-sided
distribution of adrenergic-derived myocardial cells in the adult mouse heart. The
specific distribution of these cells in the heart was visualized using 2D and 3D analysis
methods to gain a comprehensive map of their anatomical positions. The vast majority
of these cells were found on the left side of the heart. While apparently random and
uniform in the left atrium, the pattern of these cells in the free wall of the left ventricular
musculature appeared in concentrated bands near the base, mid-section, and apex.
This anatomical distribution could implicate adrenergic-derived left ventricular
myocardium in some forms of stress-induced cardiomyopathies. Further study is
required to determine the potential physiological significance of these unique findings.
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